Bisphosphonates can cause gastrointestinal side effects, including esophageal irritation, and may increase the risk of osteonecrosis of the jaw.(4, 39) Denosumab has been linked to an increased risk of fractures risk after discontinuing the drug.(1, 40) Teriparatide and abaloparatide may increase the risk of osteosarcoma, a type of bone cancer.(4, 41) Recently, romosozumab, a monoclonal antibody that targets sclerostin has been shown to both reduce bone resorption and increase bone formation. This evidence concerns the gene SOST and osteosarcoma.